Stereotaxis Inc
STXS2.445USD
+0.105+4.49%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
222.70MMarket Cap
LossP/E TTM
More Details of Stereotaxis Inc Company
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
Stereotaxis Inc Info
Ticker SymbolSTXS
Company nameStereotaxis Inc
IPO dateAug 12, 2004
CEOFischel (David Leo)
Number of employees139
Security typeOrdinary Share
Fiscal year-endAug 12
Address710 N Tucker Blvd
CityST. LOUIS
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code63101
Phone13146786100
Websitehttps://www.stereotaxis.com/
Ticker SymbolSTXS
IPO dateAug 12, 2004
CEOFischel (David Leo)
Company Executives of Stereotaxis Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Nathan Fischel, M.D.
Dr. Nathan Fischel, M.D.
Director
Director
13.92M
+0.31%
Mr. David W. Benfer
Mr. David W. Benfer
Lead Independent Director
Lead Independent Director
506.97K
+9.43%
Dr. Myriam J. Curet, M.D.
Dr. Myriam J. Curet, M.D.
Independent Director
Independent Director
345.11K
+14.49%
Mr. David Leo Fischel
Mr. David Leo Fischel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
200.00K
+42.86%
Mr. Ross B. Levin
Mr. Ross B. Levin
Independent Director
Independent Director
138.64K
+45.98%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Director
Director
89.28K
+95.75%
Dr. Arun Swarup Menawat, Ph.D.
Dr. Arun Swarup Menawat, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberly R. Peery
Ms. Kimberly R. Peery
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Nathan Fischel, M.D.
Dr. Nathan Fischel, M.D.
Director
Director
13.92M
+0.31%
Mr. David W. Benfer
Mr. David W. Benfer
Lead Independent Director
Lead Independent Director
506.97K
+9.43%
Dr. Myriam J. Curet, M.D.
Dr. Myriam J. Curet, M.D.
Independent Director
Independent Director
345.11K
+14.49%
Mr. David Leo Fischel
Mr. David Leo Fischel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
200.00K
+42.86%
Mr. Ross B. Levin
Mr. Ross B. Levin
Independent Director
Independent Director
138.64K
+45.98%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Director
Director
89.28K
+95.75%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
International
13.49M
50.12%
United States
13.43M
49.88%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fischel (Nathan)
14.91%
Dafna Capital Management, LLC
14.66%
Kiani (Joe E)
9.49%
Lagoda Investment Management, L.P.
5.04%
BlackRock Institutional Trust Company, N.A.
3.94%
Other
51.94%
Shareholders
Shareholders
Proportion
Fischel (Nathan)
14.91%
Dafna Capital Management, LLC
14.66%
Kiani (Joe E)
9.49%
Lagoda Investment Management, L.P.
5.04%
BlackRock Institutional Trust Company, N.A.
3.94%
Other
51.94%
Shareholder Types
Shareholders
Proportion
Individual Investor
28.55%
Hedge Fund
19.47%
Investment Advisor
16.89%
Investment Advisor/Hedge Fund
9.40%
Corporation
3.30%
Research Firm
0.62%
Bank and Trust
0.07%
Venture Capital
0.04%
Insurance Company
0.02%
Other
21.63%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
175
41.68M
45.77%
-4.01M
2025Q2
184
70.71M
77.86%
+13.38M
2025Q1
192
70.55M
82.04%
+9.72M
2024Q4
185
55.40M
64.94%
-4.27M
2024Q3
178
54.77M
64.71%
-4.91M
2024Q2
173
55.07M
66.24%
-4.36M
2024Q1
185
55.40M
67.15%
-4.49M
2023Q4
184
51.49M
64.77%
-9.27M
2023Q3
189
52.12M
65.60%
-9.17M
2023Q2
205
51.88M
65.54%
-5.57M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fischel (Nathan)
13.92M
15.28%
+43.67K
+0.31%
Jul 01, 2025
Dafna Capital Management, LLC
13.68M
15.02%
--
--
Jun 30, 2025
Kiani (Joe E)
8.86M
9.73%
+427.40K
+5.07%
Mar 17, 2025
Lagoda Investment Management, L.P.
4.69M
5.15%
+307.45K
+7.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.60M
3.96%
+68.06K
+1.92%
Jun 30, 2025
The Vanguard Group, Inc.
3.30M
3.63%
-231.68K
-6.56%
Jun 30, 2025
2012 Revocable Trust of Andrew Redleaf
3.08M
3.38%
--
--
Mar 17, 2025
Arbiter Partners Capital Management, LLC
2.85M
3.13%
--
--
Jun 30, 2025
Isaac (Paul J)
2.05M
2.26%
+2.05M
--
Mar 10, 2025
Essex Investment Management Company, LLC
1.54M
1.7%
-11.34K
-0.73%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Stereotaxis Inc?
The top five shareholders of Stereotaxis Inc are:
Fischel (Nathan) holds 13.92M shares, accounting for 15.28% of the total shares.
Dafna Capital Management, LLC holds 13.68M shares, accounting for 15.02% of the total shares.
Kiani (Joe E) holds 8.86M shares, accounting for 9.73% of the total shares.
Lagoda Investment Management, L.P. holds 4.69M shares, accounting for 5.15% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.60M shares, accounting for 3.96% of the total shares.
Fischel (Nathan) holds 13.92M shares, accounting for 15.28% of the total shares.
Dafna Capital Management, LLC holds 13.68M shares, accounting for 15.02% of the total shares.
Kiani (Joe E) holds 8.86M shares, accounting for 9.73% of the total shares.
Lagoda Investment Management, L.P. holds 4.69M shares, accounting for 5.15% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.60M shares, accounting for 3.96% of the total shares.
What are the top three shareholder types of Stereotaxis Inc?
The top three shareholder types of Stereotaxis Inc are:
Fischel (Nathan)
Dafna Capital Management, LLC
Kiani (Joe E)
Fischel (Nathan)
Dafna Capital Management, LLC
Kiani (Joe E)
How many institutions hold shares of Stereotaxis Inc (STXS)?
As of 2025Q3, 175 institutions hold shares of Stereotaxis Inc, with a combined market value of approximately 41.68M, accounting for 45.77% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -32.09%.
What is the biggest source of revenue for Stereotaxis Inc?
In FY2024, the -- business generated the highest revenue for Stereotaxis Inc, amounting to -- and accounting for --% of total revenue.
